Epilepsy Frequency and Risk Factors Three Years After Neonatal Seizures

Pelin Altınbezer1, Rüya Çolak2, Şebnem Çalkavur2

  • 1Department of Pediatrics, Dr. Behçet Uz Children's Education and Research Hospital, University of Health Sciences Turkey, Izmir, Turkey.

Pediatric Neurology
|October 22, 2023
PubMed

Insights

Neonatal seizures are a significant risk factor for epilepsy. Over one-third of infants with neonatal seizures developed epilepsy, with family history and neurological findings being key indicators.

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • Neonatal seizures are a major risk factor for developing epilepsy.
  • Early identification of risk factors is crucial for timely diagnosis, treatment, and improved prognosis in children.
  • Understanding epilepsy development post-neonatal seizures is a significant clinical concern.

Purpose of the Study:

  • To determine the frequency of epilepsy in children with a history of neonatal seizures.
  • To identify risk factors associated with the development of epilepsy following neonatal seizures.

Main Methods:

  • Retrospective review of hospital records for 228 infants experiencing neonatal seizures.
  • Assessment of epilepsy development and risk factors at 36 months of age.

Main Results:

  • Epilepsy was diagnosed in 40.8% of the cases.
  • Significant risk factors identified included family history of epilepsy, abnormal neurological findings, and use of multiple antiepileptic drugs.
  • Multivariate analysis confirmed family history, abnormal neurological exam at discharge, and use of at least two antiepileptic drugs as independent risk factors.

Conclusions:

  • Neonatal seizures are associated with epilepsy in over one-third of cases.
  • Infants with a family history of epilepsy, abnormal neurological findings at discharge, or on multiple antiepileptic drugs require closer monitoring for epilepsy development.
  • These findings aid in risk stratification and targeted surveillance for epilepsy in high-risk infants.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
378
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
194
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
192
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
611
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
425